Population Pharmacokinetic Analysis of Raltegravir Pediatric Formulations in HIV-infected Children 4 weeks to 18 years of age

P1066 is an open-label study of raltegravir in HIV+ youth, ages 4 weeks-18 years. Here we summarize P1066 pharmacokinetic (PK) data and a population PK model for the pediatric chewable tablet and oral granules. Raltegravir PK parameters were calculated using non-compartmental analysis. A two-compart...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Pharmacol
Autors principals: Rizk, Matthew L., Du, Lihong, Bennetto-Hood, Chantelle, Wenning, Larissa, Teppler, Hedy, Homony, Brenda, Graham, Bobbie, Fry, Carrie, Nachman, Sharon, Wiznia, Andrew, Worrell, Carol, Smith, Betsy, Acosta, Edward P.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4572519/
https://ncbi.nlm.nih.gov/pubmed/25753401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.493
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars